Abstract
Resistance to antimalarial drugs is a great threat to malaria elimination efforts and adds resurgency of malaria incidences and deaths. Rapid and indiscriminate use of drugs in the treatment of malarial infections has led to the emergence and spread of resistant strains. With condensed efforts for monitoring drugs resistance in clinical setup integrated by in vitro drug susceptibility assays and analysis of resistance markers can help in malaria eradication policy. In this chapter we discussed the demographical distribution of malaria throughout the world along with its clinical manifestations. We have also emphasized the mechanism of action underlying activity of FDA approved antimalarial drugs and also described effect of wide spectrum usage of antimalarials and combinational therapy against the deadly disease. Various factors leading to emergence of resistance including the mutation rate of the parasite for their bio-adaptation, the overall parasite load, strength of drug selection and treatment compliance. We summarize the chapter stating the number of probabilities which defines the future of antimalarial drug resistance and cumulative approaches to combat it.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Achan J, Talisuna AO, Erhart A et al (2011) Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J 10
Achtman AH, Pilat S, Law CW et al (2012) Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Sci Transl Med 4. https://doi.org/10.1126/scitranslmed.3003515
Adjei GO, Goka BQ, Binka F, Al Kurtzhals J (2009) Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children. Expert Rev Anti-Infect Ther 7:669–681
Alemu A, Shiferaw Y, Addis Z, et al (2013) Effect of malaria on HIV/AIDS transmission and progression. Parasites and vectors
Ansell J, Hamilton KA, Pinder M et al (2002) Short-range attractiveness of pregnant women to Anopheles gambiae mosquitoes. Trans R Soc Trop Med Hyg 96:113–116. https://doi.org/10.1016/S0035-9203(02)90271-3
Anvikar AR, Sharma B, Shahi BH et al (2012) Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India. Malar J 11:97. https://doi.org/10.1186/1475-2875-11-97
Armstrong D J C (1999) Infectious diseases. In: Epidemiology and infection. Harcourt International 124(3):603–605
Arrow KJ, Panosian C, Gelband H (2004) Saving lives, buying time: economics of malaria drugs in an age of resistance
Ayisi JG, van Eijk AM, ter Kuile FO et al (2003) The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 17:585–594. https://doi.org/10.1097/01.aids.0000042977.95433.37
Babiker HA, Walliker D (1997) Current views on the population structure of plasmodium falciparum: implications for control. Parasitol Today. https://doi.org/10.1016/S0169-4758(97)01075-2
Basco LK (1991) Inefficacy of amodiaquine against chloroquine-resistant malaria. Lancet 338:1460
Bauchner H, Pelton SI, Klein JO (1999) Parents, physicians and antibiotic use. Pediatrics 103:395–401. https://doi.org/10.1086/250095
Belkaid Y, Hand TW (2014) Role of the microbiota in immunity and inflammation. Cell 157:121–141
Bloland PB, Lackritz EM, Kazembe PN et al (1993) Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167:932–937. https://doi.org/10.2307/30112358
Boni MF, Smith DL, Laxminarayan R (2008) Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci 105:14216–14221. https://doi.org/10.1073/pnas.0804628105
Boudreau EF, Pang LW, Chaikummao S, Witayarut C (1991) Comparison of mefloquine, chloroquine plus pyrimethamine-sulfadoxine (Fansidar), and chloroquine as malarial prophylaxis in eastern Thailand. Southeast-Asian-J-Trop-Med-Public-Health
Breman JG (2001) The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64(1_suppl):1–11
Brockman A, Price RN, Van Vugt M et al (2000) Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg 94:537–544. https://doi.org/10.1016/S0035-9203(00)90080-4
Brocks DR, Mehvar R (2003) Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 42:1359–1382
Brossi A, Yeh HJC, Chrzanowska M et al (1988) Colchicine and its analogues: recent findings. Med Res Rev 8:77–94
Bryson HM, Goa KL (1992) Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 43:236–258. https://doi.org/10.2165/00003495-199243020-00009
Bunnag D, Poltera AA, Viravan C et al (1992) Plasmodicidal effect of desferrioxamine B in human vivax or falciparum malaria from Thailand. Acta Trop 52:59–67. https://doi.org/10.1016/0001-706X(92)90007-K
Chirenda J, Siziya S, Tshimanga M (2000) Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. Cent Afr J Med 46. https://doi.org/10.4314/cajm.v46i1.8514
Cui L, Su XZ (2009) Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti-Infect Ther 7:999–1013
Cui L, Mharakurwa S, Ndiaye D et al (2015) Antimalarial drug resistance: literature review and activities and findings of the ICEMR network. Am J Trop Med Hyg 93:57–68
Cullen KA, Mace KE, Arguin PM (2016) Malaria surveillance — United States, 2013. MMWR Surveill Summ 65:1–22. https://doi.org/10.15585/mmwr.ss6502a1
Davidson DE, Ager AL, Brown JL, et al (1981) New tissue schizontocidal antimalarial drugs. Bull World Health Organ
Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417–433. https://doi.org/10.1128/MMBR.00016-10
Demain AL, Sanchez S (2009) Microbial drug discovery: 80 years of progress. J Antibiot (Tokyo) 62:5–16. https://doi.org/10.1038/ja.2008.16
Eastman RT, Fidock DA (2009) Artemisinin-based combination therapies: A vital tool in efforts to eliminate malaria. Nat Rev Microbiol 7:864–874
Eckstein-Ludwig U, Webb RJ, Van Goethem IDA et al (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957–961. https://doi.org/10.1038/nature01813
Farooq U, Mahajan RC (2004) Drug resistance in malaria. J Vector Borne Dis
Foster S, Phillips M (1998) Economics and its contribution to the fight against malaria. In: Annals of Tropical Medicine and Parasitology
Frenk J (2006) Disease control priorities in developing countries. Salud Publica Mex 48. https://doi.org/10.1590/S0036-36342006000600011
Gaillard T, Madamet M, Pradines B (2015) Tetracyclines in malaria. Malar J 14:445
Galappaththy GNL, Tharyan P, Kirubakaran R (2013) Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 2013(10)
Gero AM, Upston JM (1992) Altered membrane permeability: a new approach to malaria chemotherapy. Parasitol Today 8:283–286. https://doi.org/10.1016/0169-4758(92)90147-T
Gleeson MT (2000) The plastid in Apicomplexa: what use is it? Int J Parasitol 30(10):1053–1070
Gogtay N, Kannan S, Thatte Urmila M et al (2013) Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008492.pub3
Goodman CA, Coleman PG, Mills AJ (1999) Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet 354:378–385. https://doi.org/10.1016/S0140-6736(99)02141-8
Gordeuk VR, Onojobi G, Schneider MF et al (2006) The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica 91(6):739–743
Grimwade K, French N, Mbatha DD et al (2003) Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J 22:1057–1063. https://doi.org/10.1097/01.inf.0000101188.95433.60
Hackstein JHP, Mackenstedt U, Mehlhorn H et al (1995) Parasitic apicomplexans harbor a chlorophyll a-D1 complex, the potential target for therapeutic triazines. Parasitol Res 81(3):207. https://doi.org/10.1007/BF00937111
Hall AP, Segal HE, Pearlman EJ et al (1975) Amodiaquine resistant falciparum malaria in Thailand. Am J Trop Med Hyg 24:575–580. https://doi.org/10.4269/ajtmh.1975.24.575
Hastings IM, Mackinnon MJ (1998) The emergence of drug-resistant malaria. Parasitology 117:411–417. https://doi.org/10.1017/S0031182098003291
Hastings IM, Watkins WM (2006) Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 22:71–77
Hemingway J, Shretta R, Wells TNC et al (2016) Tools and strategies for malaria control and elimination: what do we need to achieve a grand convergence in malaria? PLoS Biol 14:e1002380. https://doi.org/10.1371/journal.pbio.1002380
Hershko C (1989) Biological models for studying iron chelating drugs. Baillieres Clin Haematol 3:293–321. https://doi.org/10.1016/S0950-3536(89)80019-8
Hershko C, Peto TE (1988) Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 168:375–387. https://doi.org/10.1084/jem.168.1.375
Hotez PJ, Kamath A (2009) Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 3:e412
Huijben S, Paaijmans KP (2018) Putting evolution in elimination: winning our ongoing battle with evolving malaria mosquitoes and parasites. Evol Appl 11:415–430
Hyde JE (2007) Drug-resistant malaria - an insight. FEBS J 274:4688–4698
Karema C, Imwong M, Fanello CI et al (2010) Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrob Agents Chemother 54:477–483. https://doi.org/10.1128/AAC.00498-09
Kay K, Hodel EM, Hastings IM (2014) Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials. Antimicrob Agents Chemother 58:5643–5649
Kinra P, Dutta V (2013) Serum TNF alpha levels: a prognostic marker for assessment of severity of malaria. Trop Biomed 30(4):645–653
Konotey-Ahulu FID (1999) Averting a malaria disaster [12]. Lancet 354:258
Krogstad DJ, Schlesinger PH (1987) The basis of antimalarial action: non-weak base effects of chloroquine on acid vesicle pH. Am J Trop Med Hyg 36:213–220. https://doi.org/10.4269/ajtmh.1987.36.213
Kumar A, Valecha N, Jain T, Dash AP (2007) Burden of malaria in India: retrospective and prospective view. Am J Trop Med Hyg 77:69–78. doi:77/6_Suppl/69 [pii]
Kwiatkowski D, Molyneux ME, Curtis N et al (1993) Anti-tnf therapy inhibits fever in cerebral malaria. QJM 86(2):91–98. https://doi.org/10.1093/oxfordjournals.qjmed.a068783
Lallemant C, Halembokaka G, Baty G et al (2010) Impact of HIV/Aids on child mortality before the highly active antiretroviral therapy era: A study in Pointe-Noire, republic of Congo. J Trop Med 2010:1–6. https://doi.org/10.1155/2010/897176
Lell B, Kremsner PG (2002) Clindamycin as an antimalarial drug : review of clinical trials. Antimicrob Agents Chemother 46:2315–2320. https://doi.org/10.1128/AAC.46.8.2315
Lin JT, Juliano JJ, Wongsrichanalai C (2010) Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep 12:165–173
Mackinnon MJ, Hastings IM (1998) The evolution of multiple drug resistance in malaria parasites. Trans R Soc Trop Med Hyg 92:188–195
Maitland K, Newton CRJC (2005) Acidosis of severe falciparum malaria: heading for a shock? Trends Parasitol 21:11–16
Andrew R. Marks (2007) Science In Medicine
McGready R, Cho T, Samuel, et al (2001) Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 95(6): 651–656 doi: https://doi.org/10.1016/S0035-9203(01)90106-3
Molina-Cruz A, Barillas-Mury C (2014) The remarkable journey of adaptation of the Plasmodium falciparum malaria parasite to New World anopheline mosquitoes. Mem Inst Oswaldo Cruz 109:662–667. https://doi.org/10.1590/0074-0276130553
Molyneux DH, Floyd K, Barnish G, Fèvre EM (1999) Transmission control and drug resistance in malaria: A crucial interaction. Parasitol Today 15:238–240. https://doi.org/10.1016/S0169-4758(99)01453-2
Moody A (2002) Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev 15:66–78. https://doi.org/10.1128/CMR.15.1.66-78.2002
Mwangi TW, Mohammed M, Dayo H et al (2005) Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop Med Int Heal 10:530–536. https://doi.org/10.1111/j.1365-3156.2005.01439.x
Nixon GL, Moss DM, Shone AE et al (2013) Antimalarial pharmacology and therapeutics of atovaquone. J Antimicrob Chemother 68:977–985
Nosten F, White NJ (2007) Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. doi: 77/6_Suppl/181 [pii] 77:181–192
Nyunt MM, Adam I, Kayentao K et al (2010) Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther 87:226–234. https://doi.org/10.1038/clpt.2009.177
O’Meara WP, Mangeni JN, Steketee R, Greenwood B (2010) Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 10:545–555
Obaldia N, Rossan RN, Cooper RD et al (1997) WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 56:508–510. https://doi.org/10.4269/ajtmh.1997.56.508
Onyenekwe CC, Ukibe N, Meludu SC et al (2007) Prevalence of malaria as coinfection in HIVinfected individuals in a malaria endemic area of southeastern Nigeria. J Vector Borne Dis
Palmer KJ, Holliday SM, Brogden RN (1993) Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45:430–475. https://doi.org/10.2165/00003495-199345030-00009
Paul REL, Hackford I, Brockman A et al (1998) Transmission intensity and Plasmodium falciparum diversity on the northwestern border of Thailand. Am J Trop Med Hyg 58:195–203. https://doi.org/10.4269/ajtmh.1998.58.195
Peters W (1990) The prevention of antimalarial drug resistance. Pharmacol Ther 47:499–508. https://doi.org/10.1016/0163-7258(90)90067-C
Plowe CV (2003) Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol 206(21):3745–3752
Ponts N, le Roch KG (2013) Chapter 100. Malaria
Rathod HT, Govinda Rao HS (1997) Integration of polynomials over N-dimensional linear polyhedra. Comput Struct 65:829–847. https://doi.org/10.1016/S0045-7949(97)00004-7
Ridley RG, Dorn A, Vippagunta SR, Vennerstrom JL (1997) Haematin (haem) polymerization and its inhibition by quinoline antimalarials. Ann Tropical Med Parasitol 91:559–566
Rieckmann KH, McNamara JV, Frischer H et al (1968) Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum. Bull World Health Organ 38(4):625–632
Rieckmann KH, Campbell GH, Sax LJ, Ema JE (1978) Drug sensitivity of plasmodium falciparum. An In-vitro Microtechnique Lancet 311:22–23. https://doi.org/10.1016/S0140-6736(78)90365-3
Riordan JR, Deuchars K, Kartner N et al (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316:817–819. https://doi.org/10.1038/316817a0
Roy A, Cox RA, Williamson DH, Wilson RJM (1999) Protein synthesis in the plastid of Plasmo-dium falciparum. Protist 150:183–188. https://doi.org/10.1016/S1434-4610(99)70020-9
Sadhukhan GC, Mukherjee A (2016) Anti-malarial drug design by targeting Apicoplasts: new perspectives. J Pharmacopuncture 19:7–15. https://doi.org/10.3831/KPI.2016.19.001
Schapira A, France LTA, Averkiev L et al (1988) The plasmodium falciparum chloroquine in viva test: extended follow-up is more important than parasite counting. Trans R Soc Trop Med Hyg 82:39–43. https://doi.org/10.1016/0035-9203(88)90256-8
Seppälä H, Klaukka T, Vuopio-Varkila J et al (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 337:441–446. https://doi.org/10.1056/NEJM199708143370701
Shapiro RL, Lockman S (2010) Mortality among HIV-exposed infants: the first and final frontier. Clin Infect Dis 50:445–447. https://doi.org/10.1086/649887
Shaukat AM, Gilliams EA, Kenefic LJ et al (2012) Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malar J 11:207. https://doi.org/10.1186/1475-2875-11-207
Smith HJ, Meremikwu MM (2003) Iron-chelating agents for treating malaria. In: Cochrane Database of Systematic Reviews
Smith CM, Jerkovic A, Puy H et al (2015) Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. Blood 125:534–541. https://doi.org/10.1182/blood-2014-04-567149
Soh PN, Witkowski B, Olagnier D et al (2009) In vitro and in vivo properties of ellagic acid in malaria treatment. Antimicrob Agents Chemother 53:1100–1106. https://doi.org/10.1128/AAC.01175-08
Srivastava IK, Rottenberg H, Vaidya AB (1997) Atovaquone, a broad Spectrum Antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 272(7):3961–3966
Stover KR, King ST, Robinson J (2012) Artemether-Lumefantrine: an option for malaria. Ann Pharmacother 46:567–577. https://doi.org/10.1345/aph.1Q539
Sun W, Tanaka TQ, Magle CT et al (2014) Chemical signatures and new drug targets for gametocytocidal drug development. Sci Rep 4:1480–1482. https://doi.org/10.1038/srep03743
Takem EN, D’Alessandro U (2013) Malaria in pregnancy. Mediterr J Hematol Infect Dis 5:2013010. https://doi.org/10.4084/MJHID.2013.010
Uneke CJ (2007) Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: I: introduction to placental malaria. Yale J Biol Med 39:1175–1186. https://doi.org/10.1007/s00256-010-0904-6
Uneke CJ, Duhlinska DD, Ujam TN (2009) Effects of maternal Plasmodium falciparum malaria and HIV infection on birth weight in Southeastern Nigeria. Mcgill J Med
Vaidya Kuladeepa S (2012) Quantitative Buffy coat test and other diagnostic techniques for diagnosis of malaria:review of literature. Natl J Med Res
Van Eijk A, Terlouw DJ (2007) Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev
Verdrager J (1995) Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Southeast Asian J Trop. Med. Public Health
Watkins WM, Mberu EK, Winstanley PA, Plowe CV (1997) The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13:459–464. https://doi.org/10.1016/S0169-4758(97)01124-1
Wernsdorfer WH (1991) The development and spread of drug-resistant malaria. Parasitol Today 7:297–303
Wernsdorfer WH (1994) Epidemiology of drug resistance in malaria. Acta Trop 56:143–156. https://doi.org/10.1016/0001-706X(94)90060-4
Wernsdorfer WH, Payne D (1991) The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther 50(1):95–121
White NJ (1987) Combination treatment for falciparum prophylaxis. Lancet 329:680–681
White NJ (2004) Antimalarial drug resistance. JClinInvest. https://doi.org/10.1172/JCI200421682.1084
Wilson BA, Garud NR, Feder AF et al (2016) The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogens. Mol Ecol 25:42–66
Wolday D, Kibreab T, Bukenya D, Kodes R (1995) Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg 89:654–656. https://doi.org/10.1016/0035-9203(95)90431-X
Wongsrichanalai C, Sibley CH (2013) Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect 19:908–916
World Health Organization (2015) Treatment of severe malaria. Guidel Treat Malar 85:556–557. https://doi.org/10.1016/0035-9203(91)90261-V
World Health Organization (2016) World malaria report 2016
Yingchoncharoen P, Kalinowski DS, Richardson DR (2016) Lipid-based drug delivery Systems in Cancer Therapy: what is available and what is yet to come. Pharmacol Rev 68:701–787. https://doi.org/10.1124/pr.115.012070
Zumla A, Rao M, Wallis RS et al (2016) Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis 16:e47–e63. https://doi.org/10.1016/S1473-3099(16)00078-5
Zwang J, Ashley EA, Karema C et al (2009) Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: A prospective multi-Centre individual patient data analysis. PLoS One 4:e6358. https://doi.org/10.1371/journal.pone.0006358
Acknowledgements
AC thankfully acknowledge the financial support received from Shiv Nadar Foundation. VS is a recipient of SERB-NPDF from Department of Science and Technology (DST), Government of India, New Delhi. SS is a recipient of IYBA, Department of Biotechnology (DBT), Government of India, New Delhi. Authors acknowledge the support from Jawaharlal Nehru University.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chakrabarti, A., Singh, V., Singh, S. (2019). Management and Control of Antimalarial Drug Resistance. In: Mandal, S., Paul, D. (eds) Bacterial Adaptation to Co-resistance. Springer, Singapore. https://doi.org/10.1007/978-981-13-8503-2_15
Download citation
DOI: https://doi.org/10.1007/978-981-13-8503-2_15
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-8502-5
Online ISBN: 978-981-13-8503-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)